Gilead Sciences, Inc.’s Stock Price Plummets Overnight to $78.43, Registering a Sharp 10.15% Drop

Gilead Sciences, Inc. (GILD)

78.43 USD -8.86 (-10.15%) Volume: 20.38M

Overnight, Gilead Sciences, Inc.’s stock price took a hit, closing at 78.43 USD, a significant drop of -10.15% in this trading session. Despite a high trading volume of 20.38M, the biopharmaceutical company’s stock continues to struggle, with a year-to-date percentage change of -3.18%.

Latest developments on Gilead Sciences, Inc.

Gilead Sciences, Inc.‘s stock took a significant hit today, tumbling over 10% following the disappointing results of their lung cancer drug trial. The company announced that their Phase 3 EVOKE-01 study did not meet its primary endpoint, causing shares to slide. This news comes after a string of other negative updates, including the drug’s failure to improve survival rates and a decline in stock value over the past week. Gilead’s partnership with Citigroup and the recent acquisition of Digital World have also failed to boost investor confidence. With this latest setback, some are questioning whether it’s time to sell off Gilead’s stock altogether.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma